About: Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 September 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2000 (uk) 2000 സപ്തംബര്‍ 1 നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര ലേഖനം (ml) im September 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en setiembre de 2000 (ast) scientific article published on 01 September 2000 (en)
publication date	wds:Q59300523-DDFD943A-C33A-4892-94E6-C1308F382633
publication date	2000-09-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q59300523-C80A5528-7F19-4D89-BE17-4009696775A3
language of work or name	English
author name string	wds:Q59300523-25922535-D57F-4020-8D09-06929998171D wds:Q59300523-337B128B-6E50-4A2B-B73C-80C942A8F7A1 wds:Q59300523-34CB0BD3-6D85-471B-BC11-733C252D191A wds:Q59300523-40E047C9-EF8D-41FB-AC85-D3099E763CD1 wds:Q59300523-4D33A6C3-19EB-4DE8-82A7-7572F6082F3B wds:Q59300523-5341AAA4-0F70-4DD6-96CC-49FCCF60F573 wds:Q59300523-5BFCFCA5-2D01-4585-9758-B141D282E100 wds:Q59300523-7BDA5048-B430-457B-95A9-0AAFE34A0283 wds:Q59300523-84CC075A-D876-43F0-9266-46452FE5038B wds:Q59300523-A8E4DDE3-2EEA-41A3-A367-B92C33E848D9 wds:Q59300523-B6F3DCF3-639B-4F08-8CDA-09AD60F26925 wds:Q59300523-C45F12C6-83B1-4E8F-A6A4-A2C4BE2C3691 wds:Q59300523-EA960171-6876-4B9C-BFF0-E3915573AE3F
author name string	A Rossi D Amadori M Marangolo G Catalano A Ravaioli P Pacini A Volpi A Tienghi E Scarpi A Becciolini A Gambi D C Giunchi D Perroni
rdfs:label	Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study (en) Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study (nl)
skos:prefLabel	Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study (en) Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study (nl)
name	Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study (en) Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study (nl)
author	wds:Q59300523-4E45C73C-A73D-4836-AE9C-512B792F6371
author	Oriana Nanni
title	wds:Q59300523-A1699B85-95B0-4BE6-AABD-1D3F1F4682B1
title	Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study (en)
page(s)	wds:Q59300523-810551BA-0264-40B0-93A7-6FA9F292CA47
page(s)	3125-3134
instance of	wds:Q59300523-974BFAA6-57E2-4D08-B8C7-A6A03BCFBC05
instance of	scholarly article
main subject	wds:Q59300523-04F33E38-0E47-46A3-9CF4-2FC8757E84A9 wds:Q59300523-CF37E892-F509-4384-A7CF-0A86A6449FAC
main subject	wd:Q238512 wd:Q422232
PubMed ID	wds:Q59300523-EF56499C-CCC7-4935-AED7-945219EC52B3
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10963641
PubMed ID	10963641
published in	wds:Q59300523-AB17080A-13A0-4A59-802A-415E9F20E152
published in	Journal of Clinical Oncology
issue	wds:Q59300523-504E229F-2B4F-4CBF-8621-0C47F0A96AD4
volume	wds:Q59300523-8D4BE8F6-02C4-4233-9D76-8B385C91D2DA
issue	17
volume	18
DOI	wds:Q59300523-F38A0562-8722-41A9-9955-954BB5CD3EF4
DOI	http://dx.doi.org/10.1200/JCO.2000.18.17.3125
DOI	10.1200/JCO.2000.18.17.3125
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q59300523
is cites work of	Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. Biomolecular features of clinical relevance in breast cancer. Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age. Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancer Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC). Chinese Herbal Medicine as Adjunctive Therapy to Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis Improved survival after one course of perioperative chemotherapy in early breast cancer patients. long-term results from the European Organization for Research and Treatment of Cancer (EORTC) Trial 10854. Tumor markers: from laboratory to clinical utility CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cell proliferation markers in human solid tumors: assessing their impact in clinical oncology Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen Is the thymidine labeling index a good prognostic marker in breast cancer? Clinical implications of proliferation activity in T1 or T2 male gastric cancer patients Condensed chromatin staining of CKAP2 as surrogate marker for mitotic figures Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome Markers of Prognosis and Response to Treatment: Ready for Clinical Use in Oncology? A Biostatistician's Viewpoint
is cites work of	wds:Q26853619-D168F923-B850-4C43-9156-A6693BC545BD wds:Q35786472-40E1F008-CB48-4B82-908E-8FE99140516C wds:Q54765462-BC27981F-6478-4697-BBB5-8F62DFCE2577 wds:Q36356936-E0186829-1375-4EBD-B00D-085CDAD49A4E wds:Q26748777-E0B260AE-D006-4771-B11D-B59EE81FB67E wds:Q35563540-74256A76-AF7A-476C-8286-A4B175227A93 wds:Q35750303-FFD739C8-9F58-4F43-8A7F-A401EF24B118 wds:Q41128582-0A990D83-46A3-4F32-9E4F-914BBB40E0CC wds:Q43777229-1C3DE3B4-1790-4BD9-9E8B-E28E3015A3FC wds:Q33699104-C7DC5EF9-7ED9-45DC-90A0-CD0BD038AE79 wds:Q39816314-CD53BD79-12F6-46E2-AD39-77842F87D0D2 wds:Q73170784-7FA11B84-BA45-46E8-8DFD-32394D9D97D4 wds:Q35157034-3DC453DB-856B-4CC6-A0FD-ED264A38DAC5

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software